Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.
Abstract
SJ733, a newly developed inhibitor of P. falciparum ATP4, has a favorable safety profile and rapid antiparasitic effect but insufficient duration to deliver a single-dose cure of malaria. We investigated the safety, tolerability, and pharmacokinetics of a multidose SJ733 regimen and a single-dose pharmacoboost approach using cobicistat to inhibit CYP3A4, thereby increasing exposure.
| Authors | Gaur, AH; Panetta, JC; Smith, AM; Dallas, RH; Freeman, BB; Stewart, TB; Tang, L; John, E; Branum, KC; Patel, ND; Ost, S; Heine, RN; Richardson, JL; Hammill, JT; Bebrevska, L; Gusovsky, F; Maki, N; Yanagi, T; Flynn, PM; McCarthy, JS; Chalon, S; Guy, RK |
|---|---|
| Journal | EBioMedicine |
| Pages | 104065 |
| Volume | 80 |
| Date | 19/06/2022 |
| Grant ID | P30 CA021765 | NCI NIH HHS [CA] (United States) |
| Funding Body | |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016/j.ebiom.2022.104065 |